Trials / Completed
CompletedNCT02297139
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to continue to provide dasatinib to patients that are currently participating in another dasatinib trial that is ending and for which there is no other option to provide dasatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib |
Timeline
- Start date
- 2015-07-31
- Primary completion
- 2022-05-15
- Completion
- 2022-05-15
- First posted
- 2014-11-21
- Last updated
- 2023-05-06
- Results posted
- 2023-05-06
Locations
6 sites across 2 countries: France, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02297139. Inclusion in this directory is not an endorsement.